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The current National Comprehensive Cancer Network guideline 
for colon and rectal cancer designates that positron emission to-
mography-computed tomography (PET-CT) does not supplant a 
contrast-enhanced diagnostic CT scan. PET-CT should only be 
used to evaluate an equivocal finding on a contrast-enhanced CT 
scan or in patients with strong contraindications to IV contrast [1, 
2]. In addition, as of 2015, the Korea Health Insurance Review & 
Assessment Service will not pay for PET-CT as a routine follow-up 
test. In this regard, colorectal surgeons should be cautious when 
planning PET-CT as an initial staging modality in clinical practice. 
PET is a promising tool as a preoperative imaging modality for 
colorectal cancer, but still lacks firm evidence supporting its use 
as a routine test. In this issue of the Annals of Coloproctology, Yi 
et al. [3] demonstrated effectively that preoperative PET-CT is use-
ful in detecting regional and distant node metastasis in patients 
with colon cancer. Previously, Yoo et al. [4] had observed that pre-
operative PET-CT was useful in the detection of synchronous dis-
tant metastases (7.8%) and multiple primary malignancies (5.3%) 
in patients with colorectal cancer. Lee and Lee [5] also showed 
that preoperative use of PET-CT had resulted in a change in the 
treatment plan in 7% of colon-cancer patients when compared to 
the use of multidetector CT. In a recent meta-analysis, PET-CT 
showed, on a per patient basis, the highest sensitivity (94.1%) for 
the initial detection of liver metastases when compared to CT 
(83.6%) and magnetic resonance imaging (88.2%) [6]. All these 
retrospective findings are valuable; however, before the preopera-
tive use of PET-CT can be incorporated into clinical practice, 
such use must be validated through large prospective trials. 
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